KASID
Search
- Page Path
- HOME > Search
Original Article
- Inflammatory bowel diseases
- Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
- Hiep Phan, Rick A. Weideman, Daisha J. Cipher, Linda A. Feagins
- Intest Res 2020;18(3):282-288. Published online April 7, 2020
- DOI: https://doi.org/10.5217/ir.2019.09140
-
Abstract
PDF
PubReader
ePub - Background/Aims
Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without concurrent TNFi use.
Methods
Chart reviews were performed between 1996 and 2015 at the VA North Texas Healthcare System. Cases were patients with inflammatory disease, concomitant malignancy, and TNFi use while controls were patients with inflammatory disease, concomitant malignancy but no TNFi use. Cases and controls were matched for type of malignancy. Analysis was performed with log-rank tests on Kaplan-Meier curves.
Results
Thirty-six cases and 72 controls were identified. For cases, survival at 1, 2, and 5 years were 32 (89%), 31 (86%), and 29 (81%) compared to 63 (90%), 61 (87%), and 51 (73%) for the control group (P=0.985). For cases, recurrence rates at 1, 2, and 5 years were 3 (8%), 5 (14%), and 6 (17%) compared to 2 (3%), 5 (7%), and 7 (10%) for the control group (P=0.158).
Conclusions
Our findings suggest TNFi may be safely used in select inflammatory disease patients with concurrent cancer if therapy is needed for proper disease control. However, case-by-case consideration in conjunction with an oncologist is recommended while considering the apparent safety of TNFi for patients suffering from active inflammatory diseases despite having a concomitant malignancy. -
Citations
Citations to this article as recorded by
- Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study
Oh Chan Kwon, Hye Sun Lee, So Young Jeon, Min-Chan Park
Rheumatology.2025; 64(10): 5413. CrossRef - Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis
Akshita Gupta, Laurent Peyrin-Biroulet, Ashwin N. Ananthakrishnan
Clinical Gastroenterology and Hepatology.2024; 22(3): 499. CrossRef - Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors
Juan I. Ruiz, Xiudong Lei, Wu Chi-Fang, Sharon H. Giordano, Hui Zhao, Suja S. Rajan, Heather Lin, Maria E. Suarez-Almazor
Breast Cancer.2024; 31(6): 1059. CrossRef - Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model
Takeshi Takasago, Ryohei Hayashi, Yoshitaka Ueno, Misa Ariyoshi, Kana Onishi, Ken Yamashita, Yuichi Hiyama, Hidehiko Takigawa, Ryo Yuge, Yuji Urabe, Shiro Oka, Yasuhiko Kitadai, Shinji Tanaka, Kenji Fujiwara
PLOS ONE.2023; 18(3): e0283822. CrossRef - Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
Ivo Klarin, Yoshihiro Moriwaki
Case Reports in Gastrointestinal Medicine.2023; 2023: 1. CrossRef - Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
Young Bin Joo, Seung Min Jung, Yune-Jung Park, Ki-Jo Kim, Kyung-Su Park
Journal of Rheumatic Diseases.2022; 29(3): 162. CrossRef - Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef - Twenty Years of Targeted and Biologic Immunomodulatory Drugs
Julia Berman, Yarden Yavne, Yonatan Edel, Ori Elkayam, Victoria Furer, Daniel Shepshelovich
Mayo Clinic Proceedings.2022; 97(8): 1512. CrossRef - Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
Namrata Singh, Christopher I. Li
Current Opinion in Rheumatology.2021; 33(3): 292. CrossRef - Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Jihye Park, Jae Hee Cheon
Gut and Liver.2021; 15(5): 641. CrossRef
- Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study
- 9,409 View
- 164 Download
- 11 Web of Science
- 10 Crossref
First
Prev
